AIM:To evaluate the clinical efficacy of mouse nerve growth factor combined with compound anisodine on the treatment of nonarteritic anterior ischemic optic neuropathy(NAION).

METHODS: Clinical case series study was applied. One hundred and twenty-two patients with monocular onset NAION were randomly divided into three groups. Routine treatment was given to all of patients. Control group A(40 patients with 40 eyes)were undergone subcutaneous injection of compound anisodine besides superficial temporal artery, 2mL each time, twice per day; control group B(41 patients with 41 eyes)were given intramuscular injection of mouse nerve growth factor, 30μg each time, once per day; and the combined group(41 patients with 41 eyes)received compound anisodine and mouse nerve growth factor for four consecutive weeks. Visual acuity and fundus were observed every day during the treatment period. When the treatment finished, the best corrected visual acuity(BCVA), visual field and OCT were checked and recorded. The results were analyzed.

RESULTS: The recovery of visual acuity and visual field in the combined group was better than those of two control groups(P<0.05). Optic nerve fiber layer became thinner in the combined group which was still thicker than that in the control groups after the treatment, and there was significantly statistical difference(P<0.05). Visual acuity, visual field and retinal nerve fiber layer had no statistical differences between control group A and control group B(P>0.05). The effective rates of the three groups were respectively 70%(control group A), 65.9%(control group B), 92.7%(the combined group). The overall effective rate of patients in the combined group was significantly higher than that of two control groups(P<0.05), while the clinical efficacy of two control groups had no statistical difference(P>0.05).

CONCLUSION: Mouse nerve growth factor combined with compound anisodine has a remarkable effect on the treatment of NAION.